About
Leadership
Executive Team
Board of Directors
Facilities
State Disclosures
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Mpox (Monkey Pox)
Smallpox
Pipeline
Central Nervous System
TNX-102 SL
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-4200 CD45
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Press Releases
Tonix in the News
Tonix Sponsored News
Investor Presentations
Scientific Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Investor Presentations
Scientific Presentations
Program Specific Presentations
Conference Materials
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
IR Events
Investors
Investors
Overview
News & Events
Press Releases
Tonix in the News
Tonix Sponsored News
IR Events
Email Alerts
Op-Eds
Presentations
Multimedia
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
Form 8937
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Tonix Pharmaceuticals Discussion of Tonmya™ Approval
Aug 18, 2025 8:30 am EDT
Webcast
Audio
